Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors
This trial has been completed.
|Treatment||mindfulness based meditation program|
|Sponsor||Weill Medical College of Cornell University|
|Start date||May 2003|
|End date||March 2010|
|Trial size||94 participants|
|Trial identifier||NCT00278837, 0209005792(RCT)|
Women with breast cancer often suffer significant distress and disability from their disease. A practice of meditation-based stress reduction and cognitive-affective-behavioral learning may help women with breast cancer decrease their suffering and improve their quality of life.
|Intervention model||single group assignment|
|Primary purpose||supportive care|
Quality of life will be assessed by within patient differences in the FACT-G (General Functional Assessment of Cancer Treatment Scale), as well as with the disease specific subscales at baseline and at 12 months.
time frame: Subjects will complete questionnaires at baseline and closeout. Patients will participate in the meditation program weekly for 20 weeks.
Female participants from 18 years up to 101 years old.
Inclusion Criteria: All women with stage I-III breast cancer who have received treatment within the preceding year will be eligible for inclusion in the study. Exclusion Criteria: 1. Patients who refuse to participate will be excluded 2. Patients with metastatic (stage IV) cancer are excluded.
|Official title||Contemplative Self-Healing to Improve Quality of Life in Breast Cancer Survivors: the Avon Foundation Program to Reach Medically Underserved Populations|
|Principal investigator||Mary E Charlson, MD|
|Description||The objective of this study in women recently treated for breast cancer is to determine whether an intervention program consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning has the potential for reducing disabling distress and improving quality of life in a population vulnerable to the progression or recurrence of disease. Quality of life will be assessed at 12 months.|
Call for more information